glp-1 kidney cancer Glucagon-like peptide-1 medicines and Renoprotective mechanisms of glucagon-like peptide-1

Taylor Kantor, alongside his brother Anthony and Anthonys wife, Kelly, to reimagine care for cardiometabolic conditionsmaking it more accessible, individualized, and data-driven

doi: 10.1053/j.gastro.2003.12.008

The Fierce Pharma report notes that, in roughly three years, dermatologists predict the IL-23 class will account for around 18% of the total biologic market in moderate psoriasis patients and 29% in severe patients

When levels are low, progress can feel harder than it needs to be

Medicine (2015) 43(2):8893

Everyday Health: What are GLP-1 agonists, and when are they recommended for people with type 2 diabetes